Gain Therapeutics, Inc. (GANX)

Nasdaq Pharmaceutical Pharmaceutical Preparations SIC: 2834
D
Pipeline Grade

Financial Position (from SEC Filings)

$16.6M
Cash & Equivalents
$4.7M
Quarterly Burn Rate
11 mo
Est. Cash Runway
$76M
Market Cap

Estimated from most recent SEC quarterly filing. View SEC filings

Drug Pipeline (0 Assets)

No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.

Upcoming Catalysts

No upcoming catalysts detected for this company.

Active Clinical Trials (1)

NCT #TitlePhaseStatusEnrollment
NCT06732180 Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GT-02287 in Parkinson's Disease PHASE1 Recruiting 20

Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.

More Analysis

AI Stock Score

SEC EDGAR fundamental analysis with Claude AI & ChatGPT ratings for GANX.

SEC EDGAR Filings

All SEC filings for Gain Therapeutics, Inc. on EDGAR.

Full Calendar

View all upcoming FDA catalysts across all biotech companies.